Sorafenib is a drug used to treat hepatocellular carcinoma (liver cancer). However, in some patients, the liver cancer continues to grow after having an initial response to sorafenib. There is some evidence that adding the drug doxorubicin to sorafenib therapy may be beneficial for patients with liver cancer, when given as additional treatment after the cancer has grown despite sorafenib.
The purpose of this study is to evaluate the safety and effectiveness of therapy with sorafenib plus doxorubicin in patients with hepatocellular carcinoma that continued to grow despite sorafenib alone. Doxorubicin is an established chemotherapy drug used to treat many types of cancer. Sorafenib is taken orally (by mouth), while doxorubicin is given intravenously (by vein).